entecavir 1 MG Oral Tablet [Baraclude]
entecavir
RxCUI: 578459
What the CMS Formulary Data Shows for entecavir 1 MG Oral Tablet [Baraclude]
Per the CMS 2026 Part D formulary file, entecavir 1 MG Oral Tablet [Baraclude] (RxNorm concept RXCUI 578459, generic name entecavir) appears on 2 distinct formulary files spanning 8 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.
Real-world access to entecavir 1 MG Oral Tablet [Baraclude] depends on utilization management as much as tier placement: 50% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 23,172 Part D beneficiaries filled entecavir 1 MG Oral Tablet [Baraclude] in 2023, with total plan-and-beneficiary spending of $34,550,925 and an average per-beneficiary annual cost of $1,491.06. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry entecavir 1 MG Oral Tablet [Baraclude] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 8
- Coverage rate
- 0.2%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 50% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 23,172
- Total spending
- $34,550,925
- Avg per beneficiary
- $1,491.06
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering entecavir 1 MG Oral Tablet [Baraclude]
8 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
| Óptimo Plus (PPO) | TRIPLE S ADVANTAGE, INC. | T5 | Yes | $0 | PR |
| Contigo Plus (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T5 | Yes | $0 | PR |
| Brillante (HMO-POS) | TRIPLE S ADVANTAGE, INC. | T5 | Yes | $0 | PR |
| Enlace Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T5 | Yes | $0 | PR |
| ContigoEnMente (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T5 | Yes | $0 | PR |
| Ahorro Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T5 | Yes | $0 | PR |
Frequently Asked Questions
Is entecavir 1 MG Oral Tablet [Baraclude] covered by Medicare Part D?
Yes, entecavir 1 MG Oral Tablet [Baraclude] is covered by 8 Medicare Part D plans (0.2% of all Part D formularies).
What tier is entecavir 1 MG Oral Tablet [Baraclude] on Medicare Part D plans?
entecavir 1 MG Oral Tablet [Baraclude] averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 5.
Does entecavir 1 MG Oral Tablet [Baraclude] require prior authorization?
50% of Part D formularies require prior authorization for entecavir 1 MG Oral Tablet [Baraclude]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on entecavir 1 MG Oral Tablet [Baraclude]?
In 2023, total Medicare Part D spending on entecavir 1 MG Oral Tablet [Baraclude] was $34,550,925, covering 23,172 beneficiaries. The average spend per beneficiary was $1,491.06.
Read our methodology - how this data is sourced, computed, and verified.